<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several investigations revealed the significant effect of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy for <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention in patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, in the elderly population, the optimal therapeutic strategy of secondary prevention of cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> is still controversial </plain></SENT>
<SENT sid="2" pm="."><plain>We prospectively evaluated the efficacy and safety of very low-intensity <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy (target range, Thrombotest = 20-30%: INR = 1.47-1.81) for elderly cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> patients due to nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> patients (average age 80.0) with nonvalvular <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> were included in our study </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> therapy began 5 of 7 days after the embolic event </plain></SENT>
<SENT sid="5" pm="."><plain>The incidental rate of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> recurrence and <z:mp ids='MP_0001914'>bleeding</z:mp> complication were evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>During mean follow-up of 14.7 month, the annual recurrent rate of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> was 8.2% (cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> = 4.1%/year, atherothrombotic <z:hpo ids='HP_0001297'>stroke</z:hpo> = 0%/year, lacunar <z:hpo ids='HP_0001297'>stroke</z:hpo> = 4.1%/year), whereas one non-fatal <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> was observed </plain></SENT>
<SENT sid="7" pm="."><plain>Our study suggested that even in the elderly population, very low-intensity <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy may be effective, and safe with respect to prevention of <z:mp ids='MP_0001914'>bleeding</z:mp> complications, for secondary cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention </plain></SENT>
</text></document>